Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|115|6|854-855

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.115, Iss.6, 2015-06, pp. : 854-855

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma

By Mallick Rajiv   Cai Jennifer   Wogen Jenifer  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1701-1708

Informa Healthcare

Access to resources Recommend Favorite

Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 6, 2010-06 ,pp. : 1023-1025

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin

By  

Urologia Internationalis, Vol. 92, Iss. 2, 2013-11 ,pp. : 180-185

Karger

Access to resources Recommend Favorite

Paclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy

By  

Oncology Research and Treatment, Vol. 35, Iss. 10, 2012-09 ,pp. : 576-580

Karger

Access to resources Recommend Favorite

Downsizing a Tumor Thrombus of Advanced Renal Cell Carcinoma with Neoadjuvant Systemic Therapy and Resulting Histopathological Effects

By  

Urologia Internationalis, Vol. 84, Iss. 4, 2010-03 ,pp. : 479-484

Karger

Access to resources Recommend Favorite